Research programme: cancer therapeutics - Tiziana Life Sciences

Drug Profile

Research programme: cancer therapeutics - Tiziana Life Sciences

Alternative Names: Anti-cancer stem cell agent - Tiziana; Bcl3i molocules - Cardiff University/ Tiziania Life Sciences; CB1; cFLIP inhibitors; JS6; OH 14; TZLS 214; TZLS101

Latest Information Update: 06 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiff University
  • Developer Cardiff University; Tiziana Life Sciences
  • Class Small molecules
  • Mechanism of Action Apoprotein stimulants; Bcl-X protein inhibitors; Molecular motor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer

Most Recent Events

  • 01 Jun 2016 Preclinical trials in Colorectal cancer (Late-stage disease) in United Kingdom (unspecified route)
  • 08 Jan 2016 Tiziana plans a clinical trial for Breast cancer
  • 08 Jan 2016 Tiziana Life Sciences announces intention to submit IND in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top